Mendus: CML Trial Ready for Start - Redeye
Bildkälla: Stockfoto

Mendus: CML Trial Ready for Start - Redeye

Redeye is optimistic about CML as a new indication and the VITAL-CML trial. We believe it is possible to create value there more quickly than in AML.

Redeye is optimistic about CML as a new indication and the VITAL-CML trial. We believe it is possible to create value there more quickly than in AML.
Börsvärldens nyhetsbrev